A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer

CONCLUSIONS: This is the first prospective trial combining an AR antagonist and a non-steroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.PMID:38536082 | DOI:10.1158/1078-0432.CCR-23-3636

Source: Clinical Prostate Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Kunal B Desai Anthony V Serritella Walter M Stadler Peter H O'Donnell Randy F Sweis Russell Z Szmulewitz Source Type: research